Press Release | April 27, 2023
Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform
Read More
Press Release | April 26, 2023
Orbital Therapeutics Secures $270 Million in Series A Financing to Unleash Full Potential of RNA Medicines
Read More
Press Release | April 18, 2023
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
Read More
News | April 16, 2023
Dragonfly Therapeutics Announces the Publication of Preclinical Data
Read More
Press Release | April 13, 2023
Caris Life Sciences and Flare Therapeutics Announce Strategic Preferred Portfolio Partnership to Advance Flare’s Precision Oncology Pipeline
Read More
News | March 26, 2023
Investing long-term in the cell & gene therapies of the future
Read More
News | March 22, 2023
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
Read More
Press Release | March 16, 2023
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Read More
News | March 15, 2023
Passage of FDA Modernization Act 2.0 Opens Opportunities for New Alternative Methods in Drug Development
Read More
Press Release | March 13, 2023
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
Read More
Press Release | March 9, 2023
Palvella Therapeutics Announces Positive Topline Results from Phase 2 Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations, a Serious, Rare Genetic Skin Disease with No FDA-approved Therapies
Read More
News | March 7, 2023
Carisma Therapeutics Closes Merger with Sesen Bio
Read More
Press Release | March 6, 2023
Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
Read More
Press Release | March 3, 2023
Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS
Read More
Press Release | March 2, 2023
Metagenomi Recognized as One of World’s Most Innovative Companies by Fast Company
Read More
Press Release | March 1, 2023
DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting
Read More
News | February 27, 2023
Pathway to Cures Appoints Investment Committee
Read More
Press Release | February 2, 2023
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
Read More
Press Release | February 1, 2023
Dr. Joseph E. Eid, Who Led Merck’s Pioneering Clinical Development of KEYTRUDA®, joins Dragonfly Therapeutics as President of R&D
Read More
Press Release | January 31, 2023
Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board
Read More
